Peroxisome Proliferator-Activated Receptor-γ Is Deficient in Alveolar Macrophages from Patients with Alveolar Proteinosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 29, Issue 6, 2003, Pages 677-682

  Bonfield, Tracey L ^a   Farver, Carol F ^a   Barna, Barbara P ^a   Malur, Anagha ^a   Abraham, Susamma ^a   Raychaudhuri, Baisakhi ^a   Kavuru, Mani S ^a   Thomassen, Mary Jane ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SCAVENGER RECEPTOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HOMEOSTASIS; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS PROTEINOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIGENS, CD36; CELLS, CULTURED; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MACROPHAGES, ALVEOLAR; PULMONARY ALVEOLAR PROTEINOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RESPIRATORY MUCOSA; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 0348230985     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2003-0148OC     Document Type: Article

References (42)

1. Rotondo, D., and J. Davidson. 2002. Prostaglandin and PPAR control of immune cell function. Immunology 105:20-22.
2. Chinetti, G., S. Griglio, M. Antonucci, I. P. Torra, P. Delerive, Z. Majd, J.-C. Fruchart, J. Chapman, J. Najib, and B. Staels. 1998. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273:25573-25580.
3. Ricote, M., J. T. Huang, J. S. Welch, and C. K. Glass. 1999. The peroxisome proliferator-activated receptor-γ (PPARγ) as α regulator of monocyte/macrophage function. J. Leukoc. Biol. 66:733-739.
4. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82.
5. Spiegelman, B. M. 1998. PPARγ in monocytes: less pain, any gain? Cell 93:153-155.
6. Berger, J., and D. E. Moller. 2002. The mechanisms of action of PPARs. Annu. Rev. Med. 53:409-435.
7. Evans, E. D., and B. M. Spiegelman. 2000. Peroxisome proliferator- activated receptor γ ligands and artherosclerosis: ending the heartache. J. Clin. Invest. 106:629-631.
8. Jackson, S. M., F. Parhami, X.-P. Xi, J. A. Berliner, W. A. Hsueh, R. E. Law, and L. L. Demer. 1999. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19:2094-2104.
9. Seymour, J. F., and J. J. Presneill. 2002. Pulmonary alveolar proteinosis (Progress in the first 44 years). Am. J. Respir. Crit. Care Med. 166:215-235.
10. Griese, M. 1999. Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J. 13:1455-1476.
11. Ikegami, M., T. Ueda, W. Hull, J. A. Whitsett, R. C. Mulligan, G. Dranoff, and A. H. Jobe. 1996. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am. J. Physiol. 270:L650-L658.
12. Yoshida, M., M. Ikegami, J. A. Reed, Z. C. Chroneos, and J. A. Whitsett. 2001. GM-CSF regulates protein and lipid catabolism by alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:379-386.
13. Stanley, E., G. J. Lieschke, D. Grail, D. Metcalf, G. Hodgson, J. A. M. Gall, D. W. Maher, J. Cebon, V. Sinickas, and A. R. Dunn. 1994. Granulocyte/ macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. USA 91:5592-5596.
14. Dranoff, G., A. D. Crawford, M. Sadelain, B. Ream, A. Rashid, R. T. Bronson, G. R. Dickersin, C. J. Bachurski, E. L. Mark, J. A. Whitsett, and R. C. Mulligan. 1994. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264:713-716.
15. Nishinakamura, R., H. Nakagawa, Y. Hirabayashi, T. Inoue, D. Aud. T. McNeil, M. Azuma, S. Yoshida, Y. Toyoda, K. Arai, A. Miyajima, and R. Murray. 1995. Mice deficient for the IL-3/GM-CSF/IL-5 be receptor exhibit lung pathology and impaired immune response, while β IL-3 receptor deficient mice are normal. Immunity 2:211-222.
16. Reed, J. A., M. Ikegami, E. R. Cianciolo, W. Lu, P. S. Cho, W. Hull, A. H. Jobe, and J. A. Whitsett. 1999. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficicnt mice. Am. J. Physiol. 276: L556-L563.
17. Huffman, J. A., W. M. Hull, G. Dranoff, R. C. Mulligan, and J. A. Whitsett. 1995. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J. Clin. Invest. 97:649-655.
18. Kitamura, T., N. Tanaka, J. Watanabe, K. Uchida, S. Kanegasaki, Y. Yamada, and K. Nakata. 1999. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 190:875-880.
19. Tanaka, N., J. Watanabe, T. Kitamura, Y. Yamada, S. Kanegasaki, and K. Nakata. 1999. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony-stimulating factor. FEBS Lett. 442:246-250.
20. Bonfield, T. L., M. S. Kavuru, and M. J. Thomassen. 2002. Anti-GM-CSF liter predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin. Immunol. 105:342-350.
21. Bonfield, T. L., D. Russell, S. Burgess, A. Malur, M. S. Kavuru, and M. J. Thomassen. 2002. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am. J. Respir. Cell Mol. Biol. 27:481-486.
22. Seymour, J. F., I. R. Doyle, K. Nakata, J. J. Presneill, O. D. Schoch, E. Hamano, K. Uchida, R. Fisher, and A. R. Dunn. 2003. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 58:252-257.
23. Kitamura, T., K. Uchida, N. Tanaka, T. Tsuchiya, J. Watanabe, Y. Yamada, K. Hanaoka, J. F. Seymour, O. D. Schoch, I. Doyle, Y. Inoue, M. Sakatani, S. Kudoh, A. Azuma, T. Nukiwa, T. Tomita, M. Katagiri, A. Fujita, A. Kurashima, S. Kanegasaki, and K. Nakata. 2000. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 162:658-662.
24. Thomassen, M. J., T. Yi, B. Raychaudhuri, A. Malur, and M. S. Kavuru. 2000. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin. Immunol. 95: 85-92.
25. Carraway, M. S., A. J. Ghio, J. D. Carter, and C. A. Piantadosi. 1999. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 161:1294-1299.
26. Kavuru, M. S., E. J. Sullivan, R. Piccin, M. J. Thomassen, and J. K. Stoller. 2000. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 161:1143-1148.
27. Seymour, J. F., J. J. Presneill, O. D. Schoch, G. H. Downie, P. E. Moore, I. R. Doyle, J. M. Vincent, K. Nakata, T. Kitamura, D. Langton, M. C. Pain, and A. R. Dunn. 2001. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am. J. Respir. Crit. Care Med. 163:523-531.
28. Huang, J. T., J. S. Welch, M. Ricote, C. J. Binder, T. M. Willson, C. Kelly, C. K. Glass, C. D. Funk, and D. Conrad. 1999. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400:378-382.
29. Ricote, M., J. Huang, L. Fajas, A. Li, J. Welch, J. Najib, J. L. Witztum, J. Auwerx, W. Palinski, and C. K. Glass. 1998. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidixed low density lipoprotein. Proc. Natl. Acad. Sci. USA 95:7614-7619.
30. Thomassen, M. J., L. T. Buhrow, M. J. Connors, F. T. Kaneko, S. C. Erzurum, and M. S. Kavuru. 1997. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 17:279-283.
31. Bonfield, T. L., M. W. Konstan, P. Burfeind, J. R. Panuska, J. B. Hilliard, and M. Berger. 1995. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 13:257-261.
32. Raychaudhuri, B., C. J. Fisher, C. F. Farver, A. Malur, J. Drazba, M. S. Kavuru, and M. J. Thomassen. 2000. Interleukin 10 (IL-10)-mediated inhibition of inflammatory cytokine production by human alveolar macrophages. Cytokine 12:1348-1355.
33. Clark, R. B. 2002. The role of PPARs in inflammation and immunity. J. Leukoc. Biol. 71:388-400.
34. Moore, K. J., E. D. Rosen, M. L. Fitzgerald, F. Randow, L. P. Andersson, D. Altshuler, D. S. Milstone, R. M. Mortensen, B. M. Spiegelman, and M. W. Freeman. 2001. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat. Med. 7:41-47.
35. Wang, A. C. C., X. Dai, B. Luu, and D. J. Conrad. 2001. Peroxisome proliferator-activated receptor-γ regulates airway epithelial cell activation. Am. J. Respir. Cell Mol. Biol. 2001:688-693.
36. Patel, H. J., M. G. Belvisi, D. Bishop-Bailey, M. H. Yacoub, and J. A. Mitchell. 2003. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroicls: relevance for chronic obstructive pulmonary disease therapy. J. Immunol. 170:2663-2669.
37. Daynes, R. A., and D. C. Jones. 2002. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2:748-759.
38. Febbraio, M., N. A. Abumrad, D. P. Hajjar, K. Sharma, W. Cheng, S. F. A. Pearce, and R. L. Silverstein. 1999. A null mutation in murine CD36 reveals an important role in fatty acid and lipoportein metabolism. J. Biol. Chem. 274:19055-19062.
39. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve. J. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H. B. Brewer, J.-C. Fruchart, V. Clavey, and B. Staels. 2001. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7:53-58.
40. Tontonoz, P., L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans. 1998. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252.
41. Schooltink, H., and S. Rose-John. 2002. Cytokines as therapeutic drugs. J. Interferon Cytokine Res. 22:505-516.
42. Dempke, W., A. Von Poblozki, A. Grothey, and H.-J. Schmoll. 2000. Human hematopoietic growth factors: old lessons and new perspectives. Anticancer Res. 20:5155-5164.